Researcher
Frederic Rousseau
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Behavioural neuroscience
- Disciplines (KU Leuven):Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
- See also: Frederic Rousseau (Flanders Institute for Biotechnology)
Affiliations
- Switch Laboratory (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2012 → Today - Switch Lab (Research group)
Responsible
From1 Jan 2017 → Today - Switch Laboratory (VIB-KU Leuven) (Division)
Member
From1 Jan 2011 → Today - Department of Cellular and Molecular Medicine (Department)
Member
From15 Sep 2010 → 31 Dec 2010
Projects
21 - 30 of 51
- Atomic Force Microscopy Enhanced Spectroscopy to Study Strains and Seeding of Amyloids In SituFrom1 May 2020 → TodayFunding: FWO Medium Size Research Infrastructure
- Novel leavening systems for food productionFrom1 Jan 2020 → 31 Dec 2021Funding: IOF - technology validation in lab
- Cellular handling of protein aggregation gatekeepersFrom1 Jan 2020 → 31 Dec 2023Funding: FWO research project (including WEAVE projects)
- Computational analysis on the effect of post-translational modifications on amyloid interactionsFrom2 Oct 2019 → 2 Oct 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- expanding the targeted aggregation technology into the "hard-to-drug" protein spaceFrom1 Oct 2019 → 3 Mar 2023Funding: FWO Strategic Basic Research Grant
- Principles of specificity in cross-aggregation interactionsFrom1 Oct 2018 → 30 Sep 2021Funding: FWO fellowships
- Food-borne amyloids: analysis, engineering and designFrom17 Sep 2018 → 27 Feb 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Heterotypic interactions in amyloid diseasesFrom1 Jun 2018 → 12 Dec 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Investigating the mechanism of action of aggregation-inducing antimicrobial Pept-insFrom30 Oct 2017 → 21 Sep 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
- Scope and limitations of targeted aggregation as means to design novel antibacterial agentsFrom1 Oct 2017 → 30 Sep 2021Funding: BOF - Concerted Research Project from 1994
Publications
1 - 10 of 156
- Integrating physics in deep learning algorithms: a force field as a PyTorch module.(2024)
Authors: Gabriele Orlando, Joost Schymkowitz, Frederic Rousseau
Pages: btae160 - Local structural preferences in shaping tau amyloid polymorphism(2024)
Authors: Grigoria Tsaka, Rodrigo Gallardo, Dietmar Thal, Frederic Rousseau, Joost Schymkowitz
- N-glycosylation as a eukaryotic protective mechanism against protein aggregation.(2024)
Authors: Bert Houben, Matthias De Vleeschouwer, Matthew Wilson, Gert Matthijs, Joost Schymkowitz, Frederic Rousseau
Pages: eadk8173 - Modulation of hen egg white protein techno-functionality by amyloid formation(2024)
Authors: Anja Vananroye, Paula Moldenaers, Joost Schymkowitz, Frederic Rousseau, Jan Delcour
- LRRC37B is a human modifier of voltage-gated sodium channels and axon excitability in cortical neurons(2023)
Authors: Sofie Beckers, Katerina Konstantoulea, Maarten Dewilde, Frederic Rousseau, Joost Schymkowitz, Tom Theys, Joris de Wit, Pierre Vanderhaeghen
- Mechanisms and pathology of protein misfolding and aggregation(2023)
Authors: Nikolaos Louros, Joost Schymkowitz, Frederic Rousseau
Pages: 912 - 933 - Improved coalescence and creaming stability of structured oil-in-water emulsions and emulsion gels containing ovalbumin amyloid-like fibrils produced by heat and enzymatic treatments(2023)
Authors: Frederic Rousseau, Joost Schymkowitz, Jan Delcour
- TDP‑43 pathology is associated with increased tau burdens and seeding(2023)
Authors: Sandra Oliveira Tomé, Grigoria Tsaka, Klara Gawor, Philip Van Damme, Ludo Van Den Bosch, Rik Vandenberghe, Frederic Rousseau, Joost Schymkowitz, Dietmar Thal
- Exploiting the aggregation propensity of beta-lactamases to design inhibitors that induce enzyme misfolding(2023)
Authors: Laleh Khodaparast, Ladan Khodaparast, Emiel Michiels, Rodrigo Gallardo, Bert Houben, Matthias De Vleeschouwer, Frederic Rousseau, Joost Schymkowitz
- Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium(2023)
Authors: Ignace Vergote, Toon Van Gorp, Frederic Rousseau, Joost Schymkowitz
Pages: 2473 - 2484
Patents
1 - 10 of 10
- Molecules targeting ras protein (Inventor)
- Molecules targeting proteins (Inventor)
- Molecules targeting mutant ras protein (Inventor)
- Beta-lactamase inhibitors (Inventor)
- Carbon dioxide generation (Inventor)
- Molecules targeting mutant ras protein (Inventor)
- Means and methods for the prediction of amyloid core sequences (Inventor)
- Molecules targeting proteins (Inventor)
- Molecules targeting ras protein (Inventor)
- Carbon dioxide generation (Inventor)